Our most-read dry eye disease coverage of 2025 reflects a rapidly evolving landscape that blends therapeutic innovation with practical patient education. From novel dry eye formulations leveraging hyaluronic acid, trehalose, and semifluorinated alkane technology to clinician-shared strategies for clearly explaining Demodex blepharitis and its treatment, these highlights emphasize more effective, personalized, and understandable care for patients.
Hyaluronic Acid and Trehalose: New Combination for Treating Dry Eye Disease
In this clinician perspective, Kambiz Silani, OD, shares how lubricating eye drops that combine hyaluronic acid and trehalose have become a key component of his multifaceted dry eye treatment strategy. Drawing on published evidence and real-world patient cases, Dr. Silani discusses why this combination delivers faster, longer-lasting relief than HA alone and how it enhances outcomes between in-office procedures.
Read the full article here.
A new era in dry eye therapy: the semifluorinated alkane-based cyclosporine A eye drop, VEVYE
In this expert editorial, Priyanka Agarwal, PhD, explores how semifluorinated alkane technology is reshaping the therapeutic landscape, with a closer look at VEVYE, a water-free cyclosporine formulation designed to stabilize the tear film while addressing inflammation. The article examines the science behind this novel platform, its clinical performance, and why a dual-action approach may represent a meaningful shift in how clinicians break the vicious cycle of dry eye disease.
Read the full article here.
Ophthalmologists Share Best Practices for Explaining Demodex Blepharitis to Patients
Four ophthalmologists were asked how they explain the diagnosis of Demodex blepharitis (DB) to their patients. They offer scripts and tips for addressing the symptoms patients are experiencing, explaining what the Demodex mites are and how they can effectively treat the condition with a twice-daily drop, Xdemvy (lotilaner ophthalmic solution 0.25%), an FDA-approved therapeutic.
Watch the full video here.
Related Content
